The Belgium-based company UCB announced that it has completed the acquisition of US-based Ra Pharmaceuticals located in Cambridge, Massachusetts, which began last October. Former Ra Pharma shareholders received $48 in cash for each share of the company held at the closing, with a total cash transaction value of approximately $2.3 billion (€2.1 billion).
The closing of the acquisition also involves an update of UCB’s 2020 financial plan. For the current year, the company is targeting revenues between $5.50 billion (€5.05 billion) and $5.60 billion (€5.15 billion).
Discover the latest acquisitions in the biotech sector with our companion app, Born2Invest. Read the latest business news and be the first to know the most important stories from the world of finance.
UCB is accelerating its long-term innovation capabilities
The Belgian multinational will increase its potential in the treatment of myasthenia gravis thanks to zilucoplan, a peptide inhibitor of complement factor V (C5) currently in Phase III trials. The drug is in addition to a pipeline that already includes rozanolixizumab, a subcutaneously administered monoclonal antibody directed against FcRn (neonatal Fc receptor), also in Phase III.
UCB has also been awarded Ra Pharma’s ExtremeDiversity platform, which allows the production of synthetic macrocyclic peptides capable of combining the diversity and specificity of antibodies with the pharmacological properties of small molecules. The platform will accelerate the company’s long-term innovation capabilities.
“In the last 15 months we have taken several significant steps in our strategic growth path, in particular the Accelerate and Expand phase,” said Jean-Christophe Tellier, CEO of UCB. “This acquisition is a key part of this progress and an excellent complement to our strategy, which further increases our strong internal growth potential. Zilucoplan offers us the opportunity to become a leader in the treatment of people suffering from myasthenia gravis, an orphan neurological disease mediated by autoantibodies, with important unmet medical needs. It also strengthens our neurological and immunological areas, with both early and advanced projects, and adds a highly productive technology platform to our innovation engine,” Tellier concluded.
Zilucoplan is a synthetic macrocyclic peptide
The candidate drug zilucoplan is a synthetic macrocyclic peptide that inhibits complement factor V, to be administered subcutaneously once a day, currently in Phase III trials for the treatment of myasthenia gravis, with results expected in early 2021. The molecule may potentially aspire to additional indications in immune-mediated necrotizing myopathy (IMNM), amyotrophic lateral sclerosis (ALS) and other complement-mediated disorders with unmet medical needs.
In December 2019, Ra Pharma started the phase II clinical trial of zilucoplan for the treatment of IMNM. The candidate is also one of the first drugs to be selected for evaluation in a multicenter ALS study.
An extended-release formulation of zilucoplan and a potential first-class small oral C5 inhibitor are also in the early stages of development.
Myasthenia Gravis is a chronic autoimmune condition
It is a chronic autoimmune condition in which autoantibodies attack acetylcholine receptors at the neuro-muscular junction, interrupting the transmission of nerve stimuli to muscles and causing muscle weakness and fatigue. The disease affects men and women of all ages and races in the same way.
Myasthenia gravis is a rare disease that affects nearly 200,000 patients in the United States, the European Union and Japan. Sufferers may experience a number of symptoms including drooping eyelids and double vision, as well as severe muscle weakness that can become potentially lethal if it gets to the breathing muscles.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in , a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
From FinTech to Embedded Finance
Any business can incorporate FinTech services and gain additional profits by capitalizing on the loyalty of its customer base. Think...
IUL gains momentum in 2020 and prepares the launch of a new test reader
IUL Instruments, a company that designs, produces and markets automation products for microbiology laboratories has invested $727,000 (€600,000) in 3D...
Why markets and the economy continue to rattle on
Another historic week in the U.S. but markets and the economy continue to rattle on. We are seeing some divergences...
2021 begins with markets overvalued, but will it end that way?
Gold’s last all-time high was $2061 on August 6th and has spent the best part of the past six months...
Tages acquires 28 photovoltaic plants in Italy from Viridis and Equiter
With the latest acquisitions, the Tages Helios II fund has come to hold 116 MW of installed capacity, including 30...
Cannabis6 days ago
Research: Long-term use of cannabis has no effect on age-related cognitive abilities
Featured6 days ago
Trading volumes on the commodities market are at low levels
Business6 days ago
Cellnex closes purchase of Hutchison assets in Austria, Ireland and Denmark
Business6 days ago
The next step in coffee’s revolutionary journey: mushroom adaptogens